AbbVie ABBV remains a dominant force in the immunology space, powered by the continued uptake of its two blockbuster ...

AbbVie’s immunology stalwart Skyrizi continued its ascent Friday, as the drug clinched a third indication and its second FDA approval of the year. Thanks to a thumbs up from the U.S.’ drug regulator, ...

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand during July, according to data released by iSpot.tv on Monday afternoon. Skyrizi recorded an impressions share of voice (SOV) of 5.18%, ...

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

AbbVie ABBV announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its interleukin-23 (“IL-23”) inhibitor, Skyrizi ...

After Rinvoq won two new indications in as many months, AbbVie's immunology compatriot Skyrizi is getting in on the approval action. Skyrizi clinched a second nod, this time to treat adults with ...

AbbVie, Inc. ABBV announced that the FDA approved a second indication for its inflammatory drug, Skyrizi (risankizumab), to treat patients with active psoriatic arthritis. Please note that Skyrizi was ...

AbbVie ABBV announced that the FDA has granted approval to its blockbuster drug, Skyrizi to treat adults with moderately to severely active ulcerative colitis (UC) in the United States. Skyrizi’s ...

AbbVie has received European Commission approval of its anti-inflammation drug Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis, the pharmaceutical ...

- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe "We know many people living with psoriasis are looking for ...